Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21702911 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4FOLH1 | |
| SCHEMBL30467395 | 0.82 | MAP4K1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21684631 | 0.82 | MAP4K1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21684629 | 0.82 | MAP4K1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21703127 | 0.82 | MAP4K1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21684738 | 0.79 | MAP4K1 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21684740 | 0.79 | MAP4K1 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 | |
| SCHEMBL21685372 | 0.78 | MAP4K1 (0.44) | MAP4K1MEN1KMT2A | |
| SCHEMBL21685369 | 0.78 | MAP4K1 (0.44) | MAP4K1MEN1KMT2A | |
| SCHEMBL21684926 | 0.77 | MAP4K1 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNB4 4346/4885CHRNA3 4634/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNB4 4346/4885CHRNA3 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.